-+ 0.00%
-+ 0.00%
-+ 0.00%

Benitec To Highlight Key Clinical Results Observed To Date For OPMD Patients Enrolled Into BB-301 Phase 1b/2a Clinical Treatment Study And Potential For BB-301 To Transform Treatment Landscape For Patients With OPMD At 2026 MDA Clinical and Scientific Conference

Benzinga·03/10/2026 11:09:11
Listen to the news

Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment landscape for patients with OPMD.

Benitec Executive Chairman and Chief Executive Officer, Jerel A. Banks, M.D., Ph.D., will share an updated presentation detailing the significant, durable, improvements in dysphagic symptom burden and swallowing function experienced by the patients treated with low dose BB-301 and high dose BB-301.